## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.4% below STRENGTH zone (3.0-6.0%); PEG 2.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($78.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. What Makes The Cooper Companies (COO) an Investment Bet?**
- Source: Insider Monkey | 20251231T124259 | Somewhat-Bullish | Relevance: 100%
- Diamond Hill Capital's Mid Cap Strategy initiated a position in The Cooper Companies (NASDAQ: COO) during Q3 2025, viewing it as an attractive investment despite current transitory headwinds. The company, a leader in contact lenses and women's health, is expected to benefit from long-term growth in its markets. While Cooper Companies isn't among the top 30 hedge fund picks, 56 hedge funds held positions at the end of Q3, indicating significant institutional interest.

**2. BofA Slashes Price Target on Cooper Companies (COO), Keeps Buy Rating**
- Source: MSN | 20251230T020809 | Somewhat-Bullish | Relevance: 100%
- BofA Securities has reiterated its Buy rating on Cooper Companies (COO) but adjusted its price target down to $110 from $120. This update follows their analysis of the company's performance and outlook. Despite the reduced price target, the firm maintains a positive long-term view of Cooper Companies.

**3. Medical device maker CooperCompanies joins J.P. Morgan health summit**
- Source: Stock Titan | 20251230T020809 | Neutral | Relevance: 100%
- CooperCompanies (Nasdaq: COO) will present at the J.P. Morgan Healthcare Conference on January 14, 2026, with President and CEO Al White speaking at 5:15pm ET. A live and archived webcast will be available on the company's investor website. This participation is part of ongoing investor communications following solid fiscal 2025 results and strategic initiatives.

**4. First American Bank Takes $1.65 Million Position in The Cooper Companies, Inc. $COO**
- Source: MarketBeat | 20251230T131112 | Bullish | Relevance: 100%
- First American Bank recently acquired 24,011 shares of The Cooper Companies (NASDAQ:COO) worth $1.65 million during the third quarter, making it a new institutional investor. The Cooper Companies has shown strong financial performance, beating Q3 earnings and revenue estimates, and announced a $2 billion share buyback program. Analyst ratings are mixed, with a "Moderate Buy" consensus and an average price target of $90.15.

**5. Boston Trust Walden Corp Increases Stock Position in The Cooper Companies, Inc. $COO**
- Source: MarketBeat | 20251229T095205 | Bullish | Relevance: 100%
- Boston Trust Walden Corp significantly increased its stake in The Cooper Companies, Inc. (NASDAQ:COO) in Q3, adding 29,339 shares to hold a total of 1,494,960 shares valued at approximately $102.5 million. This move positions COO as the 29th-largest holding for the investment firm, amidst positive Q3 earnings for Cooper Companies and a newly authorized $2.0 billion share buyback program. Analyst consensus remains a "Moderate Buy" with an average target price of $90.15, and company insiders have also been net buyers.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |
| 2025-12-05 | Stifel | $95 | $85 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |
| 2025-12-05 | Stifel | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 10 ($1.30M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-1.1%)
- Blackrock Inc.: 7.8% (-0.8%)
- Capital World Invest: 5.4% (+25.7%)
- T. Rowe Price Invest: 5.0% (+33.2%)
- State Street Corpora: 4.4% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.15 elevated, pricing in significant growth expectations. Analyst sentiment positive (10 raises, avg +14%). Insider buying signal ($1.3M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.3B |
| Beta | 1.05 |
| 52W Range | $61.78 - $100.24 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.15 |
| Forward P/E | 16.6 |
| Current P/E | 18.2 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.5%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.42% (CS: 48) | Neutral |
| RSI_14 | 59.8 | Neutral |
| MACD Histogram | -0.30 | Bearish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 1.076x | Above |
| vs SMA200 | 1.100x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $81.96
- **Stop Loss:** $78.40 (4.3% risk)
- **Target:** $85.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 404
- **Position Value:** $33,111.84
- **Portfolio %:** 33.11%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*